Austin, Texas, 12th February 2021
Evolution Biotechnologies Inc., the Texas-based company extending the use of biological control into medically important areas, today announces the publication of the book and web resource “Bacteriophages: Biology, Technology, Therapy”, published by Springer. Details are available on line at: https://www.springer.com/gp/book/9783319419855
Edited by three members of the Evolution team, along with Professor Steve Abedon of Ohio State University, Bacteriophages: Biology, Technology, Therapy is intended to cover all major, current aspects of work with bacteriophages. This ranges from basic biology to clinical trials of phage therapeutics and from early history to nanotechnology. In so doing, the book provides a single, readily citable source covering the biology of bacteriophages and bacteriophage infection, their use across a wide range of technologies, and their evolving use as therapeutic agents.
Dr. David Harper, CEO, said “This is an important work, providing a one-stop resource on all aspects of this important technology”.
About Evolution Biotechnologies
Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.
About phage therapy
Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.